Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00277875
Status:
COMPLETED
Last Update Posted:
2009-08-27
First Post:
2006-01-13
Brief Title:
STRETCH Study Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH
Sponsor:
Synvista Therapeutics Inc
Organization:
Synvista Therapeutics Inc
Study Overview
Official Title:
The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Patients With Systolic Hypertension Before and After Receiving Oral Alagebrium for 8 Weeks
Status:
COMPLETED
Status Verified Date:
2006-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Determine whether increasing arterial distensibility by decreasing advanced glycation end-product AGE cross-link components of vascular stiffness improves a endothelial-mediated vasoreactivity at rest as assessed by flow-mediated vasodilation FMD and b endothelial-mediated vasoreactivity after exercise as assessed by pulse perfusion-mediated vasodilation PPMV
Detailed Description:
Explore several independent variables as potential independent predictors of vascular stiffness and endothelial function These parameters include patient age body mass index gender renal disease history of cardiovascular disease serum cholesterol and antihypertensive medication use
Provide insight into nitric oxide-dependent endothelial function in the setting of increased arterial stiffness by determination of substances in the nitric oxide signaling pathway specifically levels of serum cGMP serum nitrate and nitrite and serum asymmetric dimethylarginine ADMA an endogenous inhibitor of nitric oxide synthase
Provide insight into changes in AGE levels and collagen metabolism in response to alagebrium therapy specifically AGEs pentosidine carboxymethyllysine carboxyethyllysine furosine Collagen markers procollagen I carboxyterminal propeptide PICP procollagen type I N terminal propeptide PINP cross-linked carboxyterminal telopeptide of Type I collagen ICTP n-terminal propeptide of type III procollagen PIIINP
Provide insight into changes in markers of inflammation in response to alagebrium therapy specifically free and total serum matrix metalloproteinase-1MMP-1 free tissue inhibitor of metalloproteinase 1 TIMP1 intercellular adhesion molecule-1 ICAM P-selectin von Willebrand factor vWf interleukin-6 IL-6 and high-sensitivity C reactive protein hs CRP
Provide insight into nitric oxide-dependent endothelial function in the setting of increased arterial stiffness by determination of substances in the nitric oxide signaling pathway specifically levels of serum cGMP serum nitrate and nitrite and serum asymmetric dimethylarginine ADMA an endogenous inhibitor of nitric oxide synthase
Provide insight into changes in AGE levels and collagen metabolism in response to alagebrium therapy specifically AGEs pentosidine carboxymethyllysine carboxyethyllysine furosine Collagen markers procollagen I carboxyterminal propeptide PICP procollagen type I N terminal propeptide PINP cross-linked carboxyterminal telopeptide of Type I collagen ICTP n-terminal propeptide of type III procollagen PIIINP
Provide insight into changes in markers of inflammation in response to alagebrium therapy specifically free and total serum matrix metalloproteinase-1MMP-1 free tissue inhibitor of metalloproteinase 1 TIMP1 intercellular adhesion molecule-1 ICAM P-selectin von Willebrand factor vWf interleukin-6 IL-6 and high-sensitivity C reactive protein hs CRP
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None